Welcome to our dedicated page for Ani Pharmaceutic news (Ticker: ANIP), a resource for investors and traders seeking the latest updates and insights on Ani Pharmaceutic stock.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company with an active flow of corporate, clinical, and financial news. The company develops, manufactures, and commercializes therapeutics through its Rare Disease, Generics, and Brands businesses, and its communications frequently highlight progress in these areas. Investors following ANIP news can track how the Rare Disease segment, including products such as ILUVIEN and Purified Cortrophin Gel, contributes to the company’s growth alongside its generics and branded drug portfolios.
News updates for ANI often cover financial results and guidance, including quarterly earnings releases, adjusted non-GAAP metrics, and full-year outlooks. Press releases and related Form 8-K filings provide detail on net revenues by segment, the performance of key products, and management’s commentary on business trends. These disclosures also outline how Rare Disease revenues, particularly from Cortrophin Gel and ILUVIEN, compare with contributions from Generics and Brands.
ANIP news also includes clinical and medical developments, such as results from the NEW DAY clinical trial of ILUVIEN in diabetic macular edema and their presentation at major ophthalmology and retina meetings. The company reports on initiatives like the FutureVision Advisory Council, a group of retina and uveitis specialists formed to help guide its ophthalmology and retina franchise. Updates on Phase 4 trials, label transitions, and adoption trends for ILUVIEN and related products are also featured.
In addition, ANI regularly announces corporate and governance updates, including board transitions and leadership roles, as well as participation in healthcare and investor conferences hosted by organizations such as J.P. Morgan, Piper Sandler, Jefferies, H.C. Wainwright, and Morgan Stanley. These events often involve presentations or fireside chats where management discusses strategy, the transformation toward a rare disease–focused profile, and capital allocation priorities.
By monitoring ANIP news, readers can follow developments across rare disease therapeutics, generics, branded products, clinical research, and capital markets activity, all of which shape the company’s trajectory.
ANI Pharmaceuticals (Nasdaq: ANIP) has received FDA approval and launched Prucalopride Tablets, the first generic version of Motegrity®. The company secured a Competitive Generic Therapy (CGT) designation with 180-day exclusivity for this product. This achievement reinforces ANI's position as the holder of the second-highest number of CGT approvals in the U.S. Generics market. According to IQVIA data from October 2024, the U.S. annual market for Prucalopride Tablets is approximately $168.0 million.
ANI Pharmaceuticals (ANIP) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, January 14, 2025, at 2:15pm PST/5:15pm EST in San Francisco. Key executives presenting include President and CEO Nikhil Lalwani, CFO Stephen Carey, and CMO Dr. Mary Pao.
The presentation will be available via live webcast and can be accessed through the company's website at www.anipharmaceuticals.com under the Investors section's Events and Presentations area. An archived version of the webcast will remain accessible for 90 days following the event.
ANI Pharmaceuticals (Nasdaq: ANIP) announced its participation in the 36th Annual Piper Sandler Healthcare Conference. President and CEO Nikhil Lalwani and CFO Stephen Carey will host a fireside chat on Wednesday, December 4, 2024, at 3pm EST in New York City.
The event will be available via live webcast and can be accessed through the company's website at www.anipharmaceuticals.com in the Investors section under Events and Presentations. A replay will remain accessible for 90 days following the presentation.
ANI Pharmaceuticals (ANIP) reported record Q3 2024 results with net revenues of $148.3 million, up 12.5% year-over-year. The company's lead product, Cortrophin Gel, achieved record revenues of $52.6 million, growing 76.8%. Despite posting a net loss of $(24.2) million, ANI raised its 2024 guidance, expecting revenues between $594-602 million. The company completed the acquisition of Alimera Sciences, adding ILUVIEN and YUTIQ to its portfolio, and implemented a new capital structure expected to reduce annual interest expenses by $39 million.
ANI Pharmaceuticals (Nasdaq: ANIP) has announced its participation in two major healthcare conferences this November. Nikhil Lalwani, President and CEO, and Stephen Carey, CFO, will present at the Guggenheim Inaugural Healthcare Innovation Conference on November 13, 2024, at 10:00am ET, and the Jefferies London Healthcare Conference on November 20, 2024, at 2:30pm GMT/9:30am ET.
Live and archived webcasts will be available on ANI's website under the Investors section, with replays accessible for 90 days.
ANI Pharmaceuticals (NASDAQ: ANIP) has scheduled its third quarter 2024 financial results announcement for November 8, 2024, before market open. The company will host a conference call at 8:00 a.m. ET featuring CEO Nikhil Lalwani, CFO Stephen P. Carey, and Head of Rare Disease Chris Mutz. Investors can access the call toll-free at 800-445-7795 using Conference ID 4757982. A webcast will be available on the company's website under the Investors section, with a replay accessible for two weeks by calling 800-839-8389.
ANI Pharmaceuticals has received FDA approval for its Abbreviated New Drug Application (ANDA) and launched Estradiol Gel, 0.06%, a generic version of EstroGel® Gel, 0.06%. The product enters a market with annual sales of approximately $16.7 million, according to August 2024 IQVIA data. This launch represents another -competition product in ANI's portfolio, aimed at ensuring accessibility for patients and customers.
ANI Pharmaceuticals (ANIP) announced its upcoming presentation of new pre-clinical data on membranous nephropathy (MN) research at the American Society of Nephrology Kidney Week 2024 in San Diego, October 23-27. The company will showcase two poster presentations focusing on THSD7A-associated membranous nephropathy and melanocortin therapy's protective effects.
Chief Medical Officer Dr. Mary Pao highlighted the significance of their research in understanding melanocortin receptors' role in nephrotic syndrome. The presentations will be delivered by lead author Jing Liu, with sessions scheduled for October 25 and 26.
ANI Pharmaceuticals has announced the FDA approval and launch of Ketoconazole Shampoo, 2%, a generic version of Nizoral®. This approval marks another competition product for ANI, aligning with their strategic priority to launch new products addressing patient needs. The company's R&D team has been credited for this achievement.
Nikhil Lalwani, President and CEO of ANI, expressed pride in the approval and commercialization of the product. According to IQVIA data from July 2024, the U.S. annual sales for Ketoconazole Shampoo, 2% total approximately $69.2 million. This launch represents ANI's entry into a significant market segment, potentially boosting the company's revenue and market position in the pharmaceutical industry.
ANI Pharmaceuticals (ANIP) has completed its acquisition of Alimera Sciences, strengthening its Rare Disease segment. The deal adds approximately $105 million in 2024 revenue on a pro forma basis and expands ANI's footprint to 20 countries. Key points include:
1. Addition of two commercial assets: ILUVIEN® and YUTIQ® with growth potential in ophthalmology
2. Expected to drive high single-digit to low double-digit accretion in adjusted non-GAAP EPS in 2025
3. New capital structure reducing interest expense by approximately $39 million annually
4. Expansion of Rare Disease segment to ~45% of pro forma 2024 revenues
5. Potential for accelerated growth of Cortrophin Gel in ophthalmology
ANI maintains its 2024 financial guidance for the standalone company based on continued momentum across Purified Cortrophin® Gel and Generics.